Where it trades today
trading 1% of the way up its 52-week range
How the price has moved
What to weigh before acting
What Matters Now
- The read on the stock is often driven by pipeline durability, reimbursement pressure, and whether new launches can offset patent cliffs.
- ZTS trades at 11.6x earnings versus 22.0x for the sector, which means the rerating case depends on proving the discount is too harsh.
- Recent realized volatility is running around 28.2%, above the sector norm of 22.0%, so position sizing matters more than usual.
- Relative performance versus UNH, JNJ, PFE matters here because leadership inside healthcare rarely stays static for long.
Portfolio Use Case
- ZTS is more relevant for investors who want some income support alongside price appreciation, not just pure growth exposure.
- The beta profile suggests it can fit a quality or lower-volatility sleeve more naturally than a high-octane tactical basket.
- The stock becomes more useful when paired with an explicit catalyst watchlist, because sector sentiment can shift quickly around policy, rates, or pipeline news.
What Would Change the View
- Volatility is already above the sector norm, so even a correct long-term thesis can be painful if the position size is too aggressive.
- The view would need revisiting if peers such as UNH, JNJ, PFE start winning the marginal flow or posting cleaner operating momentum.
Methodology
- Price, market cap, beta, yield, and liquidity fields for ZTS come from Yahoo Finance quote and summary data.
- 30-day volatility is calculated from recent daily returns and annualized using a 252-trading-day convention.
- Sector context uses stored benchmark averages for Healthcare so each page compares the ticker against a stable peer baseline rather than against the whole market.
- Peer comparisons use the Portfolio Terminal coverage set and highlight nearby listed alternatives such as UNH, JNJ, PFE.
Sources
- Yahoo Finance quote dataopen →
Live quote, valuation, beta, yield, and volume fields used for ZTS. Last refresh: Sep 18, 2026, 10:56 PM.
- Portfolio Terminal methodologyopen →
Explains how analytics, refresh cadence, and portfolio interpretation work across the product.
- Peer set and coverage context
Comparative context for this page is anchored around nearby tracked names such as UNH, JNJ, PFE.
What Zoetis Inc. does
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care…
Employees
14,500
Industry
Drug Manufacturers - Specialty & Generic
Headquarters
Parsippany, United States
What analysts expect
ZTS carries a buy consensus from 15 analysts, with an average price target of $96.00 versus $71.40 today (+34.5%). Targets are estimates and can move quickly after earnings.
Consensus aggregated by Yahoo Finance. Targets are estimates, not forecasts.
How the business is doing
ZTS generated $9.53B in trailing revenue (-0.2% year over year), with a 27.7% net margin, and $2.02B of free cash flow, against $7.58B of net debt.
The numbers, year by year
| Fiscal year | Revenue | Gross profit | Operating income | Net income | EPS | Free cash flow |
|---|---|---|---|---|---|---|
| 2025 | $9.47B | $6.80B | $3.60B | $2.67B | $6.03 | $2.28B |
| 2024 | $9.26B | $6.54B | $3.39B | $2.49B | $5.47 | $2.30B |
| 2023 | $8.54B | $5.98B | $3.07B | $2.34B | $5.08 | $1.62B |
| 2022 | $8.08B | $5.63B | $2.93B | $2.11B | $4.51 | $1.33B |
When it reports next
Estimates aggregated by Yahoo Finance. Dates move and estimates change until the report lands.
How it sits in healthcare
Defensive sector including pharmaceuticals, biotech, medical devices, and healthcare services.
The companies it competes with
ZTS beside the healthcare names it is usually measured against.
What the chart is saying
Zoetis Inc. trades at $71.40, 52.0% below its 52-week high. With a beta of 0.73, it shows less sensitivity to what the wider market does.
Questions people ask about it
Is ZTS a good buy right now?
Zoetis Inc. trades at 11.6x earnings. This is below market average, potentially undervalued. Current risk level is Medium based on 28.2% volatility.
Does ZTS pay dividends?
Yes, Zoetis Inc. offers a dividend yield of 2.90%. That is roughly $2.07 per share a year.
How volatile is ZTS?
With 30-day annualized volatility of 28.2% and beta of 0.73, ZTS is classified as Medium risk. The stock tends to be more stable than the market average.
What is the analyst price target for ZTS?
The average analyst price target for Zoetis Inc. (ZTS) is $96.00 based on 15 analyst estimates, about 34.5% above the current price of $71.40. The published range runs from $80.00 to $155.00.
How much revenue does ZTS generate?
Zoetis Inc. reported $9.53B in trailing twelve-month revenue. Revenue growth is running at -0.2% year over year. Net margin sits at 27.7%. Figures are aggregated from company filings by Yahoo Finance and refresh on an hourly cadence.